Comparison of the current of the modified CALGB10403 with the original publication and a historical cohort of the Mexican AYA population
| . | Study publication . | CALGB 10403 original publication . | Historical cohort Mexican AYA population . |
|---|---|---|---|
| No. of patients | 95 | 295 | 376 |
| Age, median (range) | 23 y (14-49) | 24 y (17-39) | 22 y (14-39) |
| High risk, n (%) | High risk (45) Hyperleukocytosis (41) Unfavorable cytogenetics (15) Aberrant CRLF2 expression n = 14 (50) | Unfavorable cytogenetics 18 (7) Aberrant CRLF2 expression n = 131 (21) WBC < 30 × 109/L > 30 (26) | 182 (48) |
| Induction death rate (%) | 7 (7) | 9 (3) | 26 (7) |
| CR after induction (%) | 79 (83) | 263 (89) | 301 (80) |
| OS (events = deaths) | No events, 25 of 95 2 y OS, 72.1% (95% CI, 61.6-82.4) | No events, 105 of 295 3 y OS, 73% (95% CI, 68-78) | No events, 410 of 559 3 y OS, 26% Median OS, 14.1 mo (11.7-16.4) |
| Treatment-related deaths | No events, 9 of 95 (9) | No events, 8 of 295 (3) | No events, 98 of 376 (26) |
| Allo HSCT | 8 of 95 (8) in CR1 or CR2 | 20 of 263 (8) in CR1 | 25 of 376 (7) in CR1 or CR2 |
| . | Study publication . | CALGB 10403 original publication . | Historical cohort Mexican AYA population . |
|---|---|---|---|
| No. of patients | 95 | 295 | 376 |
| Age, median (range) | 23 y (14-49) | 24 y (17-39) | 22 y (14-39) |
| High risk, n (%) | High risk (45) Hyperleukocytosis (41) Unfavorable cytogenetics (15) Aberrant CRLF2 expression n = 14 (50) | Unfavorable cytogenetics 18 (7) Aberrant CRLF2 expression n = 131 (21) WBC < 30 × 109/L > 30 (26) | 182 (48) |
| Induction death rate (%) | 7 (7) | 9 (3) | 26 (7) |
| CR after induction (%) | 79 (83) | 263 (89) | 301 (80) |
| OS (events = deaths) | No events, 25 of 95 2 y OS, 72.1% (95% CI, 61.6-82.4) | No events, 105 of 295 3 y OS, 73% (95% CI, 68-78) | No events, 410 of 559 3 y OS, 26% Median OS, 14.1 mo (11.7-16.4) |
| Treatment-related deaths | No events, 9 of 95 (9) | No events, 8 of 295 (3) | No events, 98 of 376 (26) |
| Allo HSCT | 8 of 95 (8) in CR1 or CR2 | 20 of 263 (8) in CR1 | 25 of 376 (7) in CR1 or CR2 |
HSCT, hematopoietic stem cell transplant; WBC, white blood cell.